Bloomberg’s Ana Monteiro was kind enough to quote from my tariff relief paper in a recent piece:
While some duties have been relaxed to help with importing inputs needed for the coronavirus response, repealing tariffs related to health care altogether is something that Ryan Young, a senior fellow at the Competitive Enterprise Institute, in a July 8 paper said would have the immediate benefit of lowering costs for equipment and medical treatments. He argued that removing all duties imposed since 2017 would “aid economic recovery by reducing businesses’ supply costs,” and provide them some regulatory certainty.
The CEI’s Young also called for tariff-making authority to be moved back to Congress. That would mean repealing:
-
Section 232 of the 1962 Trade Expansion Act, which allows for tariffs without a vote by Congress if imports are deemed a national-security threat;
-
Sections 201 of the 1974 Trade Act, which gives the president authority to impose trade restrictions;
-
Section 301 of the 1974 Trade Act, which President Donald Trump has used to impose tariffs on French and Chinese goods.
Inertia Wins! 